Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

Inclusion Criteria: 1. Patient has documented diagnosis of advanced solid tumor for which no standard systemic therapy exists 2. Patient has normal or abnormal renal organ function 3. Patient has provided written informed consent prior to any screening procedures Exclusion Criteria: 1. Patient needing valproic acid for any medical condition during the study or within 5 days prior to the first panobinostat dose 2. Patient received prior treatment with DAC inhibitors including panobinostat 3. Patient requiring dialysis 4. Patient requiring diuretics unless patient is taking potassium sparring diuretics 5. Patient has acute renal failure, history of transplant, ESRD (however acceptable severe renal impaired group) 6. Female patient who is pregnant or breast feeding or with childbearing potential and not willing to use a double method of contraception up to 3 months after the end of study treatment. Male patient who is not willing to use a barrier method of contraception up to 3 months after the end of study treatment. Other protocol-defined inclusion/exclusion criteria may apply